Table 2.
Overall survival (OS) analysis of Chinese and U.S. SCCE patients
| Group ONE (n = 137) | Group TWO (n = 385) | |||||||
|---|---|---|---|---|---|---|---|---|
| No. | MST (m, 95% CI) | 5‐year OS (%) | P value | No. | MST (m, 95% CI) | 5‐year OS (%) | P value | |
| Age | ||||||||
| ≤60 | 74 | 16.0 (13.2‐18.8) | 11.1 | 101 | 11.0 (6.9‐15.1) | 11.8 | ||
| >60 | 63 | 12.5 (8.2‐16.8) | 13.2 | 0.513 | 284 | 7.0 (5.7‐8.3) | 6.1 | 0.001 |
| Gender | ||||||||
| Male | 101 | 14.5 (10.9‐18.1) | 11.9 | 238 | 8.0 (6.7‐9.3) | 8.1 | ||
| Female | 36 | 15.5 (12.6‐18.4) | 10.9 | 0.832 | 147 | 8.0 (6.2‐9.8) | 7.0 | 0.756 |
| VALSG stage | ||||||||
| Localized | 37 | 20.0 (10.9‐29.1) | 22.7 | 64 | 19.0 (13.5‐24.5) | 18.8 | ||
| Regional | 57 | 14.0 (10.5‐17.5) | 10.0 | 72 | 12.0 (9.2‐14.8) | 15.2 | ||
| Extensive | 43 | 9.0 (6.5‐11.5) | 5.4 | <0.001 | 199 | 5.0 (3.2‐6.8) | 2.1 | |
| Unstaged | 50 | 8.0 (13.5‐24.5) | 6.0 | <0.001 | ||||
| Pathological subtype | ||||||||
| Pure SCCE | 117 | 14.0 (11.2‐16.8) | 12.0 | 367 | 8.0 (6.9‐9.1) | 8.0 | ||
| Combined SCCE | 20 | 17.0 (15.7‐18.3) | 13.8 | 0.331 | 18 | 9.0 (6.2‐11.8) | 0 | 0.606 |
| Surgery | ||||||||
| Nonradical/no | 45 | 12.0 (7.5‐16.5) | 9.5 | 354 | 7.0 (6.0‐8.0) | 7.2 | ||
| Radical | 92 | 17.0 (14.6‐19.4) | 13.2 | 0.046 | 31 | 16.0 (11.7‐20.3) | 12.9 | 0.041 |
| Radiotherapy | ||||||||
| No | 92 | 12.0 (8.5‐15.5) | 9.2 | 211 | 5.0 (3.5‐6.5) | 2.4 | ||
| Yes | 45 | 17.0 (13.2‐20.8) | 16.0 | 0.172 | 174 | 12.0 (9.1‐14.9) | 14.1 | <0.001 |
| Chemotherapy | ||||||||
| No | 32 | 9.0 (7.5‐10.5) | 7.6 | 130 | 2.0 (1.4‐2.6) | 0 | ||
| Yes | 105 | 15.5 (13.1‐17.9) | 13.0 | 0.016 | 255 | 11.0 (9.3‐12.7) | 11.7 | <0.001 |
| Tumor location | ||||||||
| Upper third | 19 | 17.0 (11.6‐22.4) | 27.5 | 25 | 9.0 (7.1‐10.9) | 5.3 | ||
| Mid‐third | 83 | 15.5 (11.8‐19.2) | 7.1 | 98 | 9.0 (6.7‐11.3) | 7.8 | ||
| Lower third | 35 | 12.0 (6.6‐17.4) | 14.6 | 0.340 | 173 | 8.0 (6.2‐9.8) | 10.1 | 0.904 |
| Primary Tumor length | ||||||||
| <5 cm | 57 | 18.0 (15.7‐20.3) | 13.6 | |||||
| ≥5 cm | 80 | 11.0 (8.3‐13.7) | 10.8 | 0.022 | ||||
| T stage | ||||||||
| T1/2 | 50 | 18.0 (14.2‐21.8) | 11.5 | |||||
| T3/4 | 87 | 13.0 (10.6‐15.4) | 11.8 | 0.082 | ||||
| N stage | ||||||||
| N‐ | 37 | 20.0 (10.9‐29.1) | 22.7 | |||||
| N+ | 100 | 12.0 (9.7‐14.3) | 8.3 | 0.001 | ||||
| TNM stage | ||||||||
| I/IIA | 35 | 19.0 (13.9‐24.1) | 21.7 | |||||
| IIB | 22 | 18.0 (12.8‐23.2) | 13.9 | |||||
| III/IV | 80 | 11.0 (8.5‐13.5) | 9.5 | 0.013 | ||||
| Family history | ||||||||
| No | 116 | 15.0 (12.5‐17.5) | 12.6 | |||||
| Yes | 19 | 15.0 (10.1‐19.9) | 9.1 | 0.804 | ||||
| Multimodal treatment | ||||||||
| Local | 31 | 9.0 (7.6‐10.4) | 11.8 | |||||
| Systemic | 11 | 8.0 (5.8‐10.2) | 0 | |||||
| Local+systemic | 95 | 17.0 (14.6‐19.4) | 14.2 | <0.001 | ||||
SCCE, small cell carcinoma of the esophagus; VALSG, the Veterans’ Administration Lung Study Group; Local, surgery/radiotherapy; Systemic, chemotherapy.